Eli Lilly says Taltz met co-primary endpoints in Phase 3 plaque psoriasis study
Eli Lilly announced that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89% of patients treated with Taltz achieved a significant 75% improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score and 81% of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin. Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress, or EADV, in Madrid, Spain. Based on these results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis, the company said. Lotus Mallbris, vice president of immunology development at Lilly, added, "We're pleased to see positive results for Taltz in pediatric patients. These results build on more than five years of safety and efficacy data in adults and support the potential for Taltz in this new population, pending regulatory approvals."